证券代码：600056 证券简称：中国医药 公告编号：临 2026-002 号 中国医药健康产业股份有限公司 关于子公司收到《税务事项通知书》暨补缴税款相关 事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司海南通用三洋药业有限公司（以下简称"三洋药业"）和海南康力药业有限公 司（以下简称"康力药业"）分别收到国家税务总局海口市税务局第一税务分局 关于要求补缴相关税款的《税务事项通知书》（以下简称"通知书"），现将有 关情况公告如下： 一、基本情况 三洋药业需补缴税款2,148.62万元，滞纳金约1,074.29万元；康力药业需 补缴税款2,128.26万元，滞纳金约1,170.61万元。合计需补缴税款及滞纳金约 6,521.78万元。本次补缴不涉及税务行政处罚。三洋药业和康力药业将根据要求 进行补缴。 二、对公司的影响和风险提示 根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》，上 述补缴税款及滞纳金事项不属于前期会计差错，不涉 ...

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved drug, Clarithromycin, is indicated for the treatment of infections caused by sensitive pathogenic bacteria, including lower respiratory tract infections, upper respiratory tract infections, and skin and soft tissue infections [1]

三洋药业需补缴税款2,148.62万元，滞纳金约1,074.29万元；康力药业需补缴税款2,128.26万元，滞纳金 约1,170.61万元。合计需补缴税款及滞纳金约6,521.78万元。本次补缴不涉及税务行政处罚。三洋药业和 康力药业将根据要求进行补缴。 格隆汇12月31日丨中国医药(600056.SH)公布，公司下属全资子公司海南通用三洋药业有限公司（以下 简称"三洋药业"）和海南康力药业有限公司（以下简称"康力药业"）分别收到国家税务总局海口市税务 局第一税务分局关于要求补缴相关税款的《税务事项通知书》（以下简称"通知书"），现将有关情况公 告如下： ...

三洋药业需补缴税款2,148.62万元，滞纳金约1,074.29万元；康力药业需补缴税款2,128.26万元，滞纳金 约1,170.61万元。合计需补缴税款及滞纳金约6,521.78万元。本次补缴不涉及税务行政处罚。三洋药业和 康力药业将根据要求进行补缴。 格隆汇12月31日丨中国医药(600056.SH)公布，公司下属全资子公司海南通用三洋药业有限公司（以下 简称"三洋药业"）和海南康力药业有限公司（以下简称"康力药业"）分别收到国家税务总局海口市税务 局第一税务分局关于要求补缴相关税款的《税务事项通知书》（以下简称"通知书"），现将有关情况公 告如下： ...

Meeting Overview - The 34th meeting of the 9th Board of Directors of China Pharmaceutical Health Industry Co., Ltd. was held on December 29, 2025, combining in-person and communication methods, chaired by Chairman and General Manager Yang Guang [2] - All 8 directors attended the meeting, and the meeting complied with the relevant provisions of the Company Law and the Articles of Association, making the resolutions valid [4][5] Resolutions Passed - The board approved the proposal to acquire 70% equity of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for a cash consideration of 525 million RMB [6][14] - The board also approved the revision of the "System Management Measures" [8][9] Transaction Details - The acquisition aims to enhance the company's comprehensive strength in pharmaceutical research and development, addressing current shortcomings in its R&D system and achieving a full industry chain from research to production [18] - The total transaction amount is 525 million RMB, funded by the company's own and/or self-raised funds [18] - After the transaction, the company will hold 70% of Zezheng Pharmaceutical, which will become a subsidiary included in the company's consolidated financial statements [18] Financial Overview of the Target Company - As of September 30, 2025, Zezheng Pharmaceutical had total assets of 421.63 million RMB and net assets of 264.62 million RMB, with a revenue of 107.29 million RMB and a net loss of 40.85 million RMB for the first nine months of 2025 [47] - The valuation of Zezheng Pharmaceutical was assessed at 758.84 million RMB using the income approach, indicating a significant increase in value [48] Strategic Importance of the Transaction - The acquisition is expected to strengthen the company's position in the pharmaceutical R&D sector, allowing for deeper integration of technology, market, and resources, and enhancing competitiveness [63] - The management of Zezheng Pharmaceutical will be arranged according to the agreement, ensuring the company's legal rights and control [63]

Group 1 - Zijin Mining expects a net profit of approximately 51-52 billion yuan for 2025, representing a year-on-year increase of about 59%-62% due to growth in gold, copper, and silver production and sales prices, along with a significant increase in lithium carbonate production [1] - Tianpu Co. has seen its stock price rise by 718.39% from August 22 to December 30, leading to a suspension for stock trading review due to significant deviation from the company's fundamentals [1] - Salt Lake Co. plans to acquire 51% of Wenkang Salt Lake for 4.605 billion yuan, which will enhance its competitive edge in lithium and potassium resource development [1] Group 2 - Mingde Bio intends to acquire 100% of Wuhan Bikaier Rescue Supplies Co. in a cash transaction, which is expected to constitute a major asset restructuring [2] - Jiamei Packaging has announced that it may apply for a trading suspension if its stock price continues to rise abnormally, despite no significant changes in its fundamentals [2] Group 3 - Jinpan Technology signed a contract worth approximately 696 million yuan for an overseas data center project, which is expected to positively impact the company's long-term performance [3] Group 4 - China Pharmaceutical plans to acquire 70% of Zezheng Pharmaceutical for 525 million yuan [4] - Shengxin Lithium Energy intends to acquire 30% of Qicheng Mining for 2.08 billion yuan to increase its control over Huirong Mining [5] - China Aluminum's subsidiary plans to acquire 51% of Yun Aluminum Logistics for 264 million yuan [5]

证券日报网讯 12月30日，中国医药发布公告称，公司第九届董事会第34次会议于2025年12月29日召 开，审议通过《关于收购则正医药70%股权的议案》《关于修订的议案》。 （文章来源：证券日报） ...

Group 1 - Deeply Housing A's controlling shareholder has decided to terminate the agreement to transfer 7.07% of the company's shares to Dongfang Asset, which will not lead to any changes in the controlling shareholder or actual controller of the company [1] - Wuzhou New Spring's controlling shareholder has reduced its stake by 2.73%, with a total of 9.99 million shares sold, and confirmed that there are no undisclosed significant matters affecting the company's stock price [2] - Baiwei Storage's subsidiary plans to acquire 380,066 shares of Niu Xin Semiconductor for 20 million yuan, representing 0.8446% of its total share capital, focusing on high-speed transmission and interconnection technology [3] Group 2 - Zhaofeng Co. plans to change part of its raised funds to invest in the industrialization of embodied intelligent robots and high-end precision components for automotive intelligent driving, with a total investment of 153 million yuan [4] - Tianpu Co. has seen its stock price increase by 718.39% from August 22 to December 30, leading to a suspension for verification due to significant deviation from the company's fundamentals [5] - Jingce Electronics has signed contracts to sell semiconductor front-end detection equipment worth a total of 571 million yuan [6] Group 3 - Jiamei Packaging has announced that it may apply for a suspension of trading if its stock price continues to rise abnormally, despite no significant changes in its fundamentals [7] - Zijin Mining expects a net profit of approximately 51 billion to 52 billion yuan for 2025, an increase of 59%-62% year-on-year, driven by rising sales prices of gold, copper, and silver [8][9] - Mingde Bio plans to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., which is expected to constitute a major asset restructuring [10] Group 4 - Shengxin Lithium Energy intends to acquire a 30% stake in Qicheng Mining for 2.08 billion yuan, with the latter's lithium mine development progressing [11] - Chaojie Co.'s controlling shareholder has completed a share reduction plan, reducing its stake to 45.37% without affecting the company's control [12] - Shichuang Energy's actual controller has undergone a change in indirect shareholding due to a divorce, but this will not affect the company's control [13] Group 5 - Yilake Co. plans to acquire 51% of Wuku Salt Lake for 4.605 billion yuan, which will become a subsidiary of the company upon completion of the transaction [14] - Various companies have reported significant contract wins, including Changjiang Electric Power's cash dividend distribution and multiple projects won by China Western Electric [18]

Suspension and Resumption - Tianpu Co., Ltd. has suspended trading due to a significant deviation of its stock price from the company's fundamentals. The company has no plans to engage in artificial intelligence-related business and has not signed any framework cooperation agreements with shareholder Zhonghao Xinying. There are no asset injection plans related to Zhonghao Xinying [1] Share Buybacks - Zhongju High-tech plans to repurchase shares worth between 300 million to 600 million yuan for cancellation and reduction of registered capital [2] - Baili Tianheng intends to repurchase shares valued at 100 million to 200 million yuan [2] Mergers and Acquisitions - Shengxin Lithium Energy plans to acquire 30% equity of Qicheng Mining for 2.08 billion yuan, aiming for 100% ownership. Qicheng Mining's subsidiary, Huirong Mining, holds mining rights for the Muro Lithium Mine, which has confirmed Li2O resources of 989,600 tons with an average grade of 1.62%, making it one of the highest-grade lithium mines in Sichuan, with a production scale of 3 million tons per year [3] - Mingde Bio plans to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. in cash. The target company is one of the early adopters of international first aid concepts and technologies, focusing on emergency rescue business [3] - Yilake Co., Ltd. intends to acquire 51% equity of Minmetals Salt Lake for 4.605 billion yuan [3] - CITIC Special Steel's wholly-owned subsidiary, Taifu Technology, plans to acquire 100% equity of Fujing Special Co., Ltd. from Guangzhou Airport for 1.51 billion yuan. Fujing Special is one of the world's top three independent steel traders [3] - China National Pharmaceutical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan. Zezheng Pharmaceutical specializes in the research and development of modified new drugs and complex formulations [3] External Investments and Daily Operations - Wanli Stone plans to establish a joint venture to develop and operate the Kuerdai Molybdenum Uranium polymetallic mine resources [4] - China Nonferrous Metals plans to invest 1.741 billion yuan in the expansion project of a lead-zinc mine with an annual capacity of 1.65 million tons [5] - Taihe Technology plans to transform its original lithium iron phosphate production facility to produce sodium iron phosphate, achieving an annual production capacity of 10,000 tons [5] - Zhaofeng Co., Ltd. intends to invest 1.53 billion yuan in the industrialization project of embodied intelligent robots and high-end precision components for automotive intelligent driving [5] - Datang Power plans to increase its investment in Datang Nuclear Power Company by 617 million yuan for projects including the Liaoning Xudabao Nuclear Power Project and Ningde Second Nuclear Power [5] - Huaxia Airlines plans to purchase three A320 series aircraft, with an estimated transaction amount of approximately 2.763 billion to 2.976 billion yuan [6] - Jingce Electronics plans to sell multiple semiconductor front-end testing equipment to customers, totaling 571 million yuan [7] - Tianyuan Co., Ltd. plans to invest 1.483 billion yuan in a project to build an annual production capacity of 100,000 tons of titanium dioxide using the chloride method [8] - Baiwei Storage plans to acquire 380,000 shares of Niu Xin Semiconductor for 2 million yuan, with the National Integrated Circuit Fund Phase II holding a 6.76% stake in the latter [9] - Jinpan Technology has signed a contract for a data center project with overseas clients, amounting to 98.992 million USD [9] Performance Changes - Zijin Mining expects a net profit attributable to shareholders of approximately 51 billion to 52 billion yuan for the fiscal year 2025, representing a year-on-year increase of about 59% to 62%. The sales prices of gold, copper, and silver have increased year-on-year [10]

Core Insights - China Medical (600056.SH) announced the acquisition of 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for RMB 525 million, marking a significant step in enhancing its R&D capabilities and integrating the entire industry chain from R&D to production [1][2] Group 1: Acquisition Details - The acquisition will allow Zezheng Pharmaceutical to become a subsidiary of China Medical, thus included in its consolidated financial statements [1] - Zezheng Pharmaceutical, established in 2017, specializes in modified new drugs and complex formulations, with over 100 R&D projects submitted to the National Medical Products Administration and 55 drug approvals obtained [1] Group 2: Strategic Implications - The acquisition aims to fill the gaps in China Medical's capabilities in generic drugs, modified new drugs, and innovative drugs, facilitating the upgrade of its product pipeline [1] - By combining Zezheng Pharmaceutical's CRO services with China Medical's industrial capacity, the transaction is expected to accelerate the conversion of technological achievements and create a competitive edge in high-barrier areas like complex formulations [1] - The retention of Zezheng Pharmaceutical's core team post-acquisition is intended to ensure operational stability [1] Group 3: Industry Context - Industry experts highlight that in the context of national encouragement for pharmaceutical innovation and the normalization of generic drug consistency evaluations, CRO companies with comprehensive R&D capabilities and differentiated technology platforms hold unique advantages [2] - The integration of resources through this acquisition is anticipated to foster a collaborative ecosystem of "R&D—Manufacturing—Commercialization," enhancing overall competitiveness [2]